Table 2 Daily and 3-day average comparison of subjective appetite measurements calculated as mean area under the curve in response to placebo or PGX for the per-protocol subject group

From: Effect of PGX, a novel functional fibre supplement, on subjective ratings of appetite in overweight and obese women consuming a 3-day structured, low-calorie diet

Score

Day

Placebo

PGX

% Change

P-value

Prospective consumption

1

457.2±29.4

432.5±27.8

−5.4

0.358

 

2

477.9±33.1

427.1±29.6

−10.6

0.079

 

3

471±32.5

401.8±27.7

−14.7

0.017

 

Average days 1–3

468.6±28.9

420.2±25.9

−10.3

0.026

Desire

1

432.5±29.4

428.8±29.1

−0.9

0.894

 

2

456.3 ±34.2

416.9±31.3

−8.6

0.273

 

3

427.7±35

387.9±31.7

−9.3

0.280

 

Average days 1–3

438.6±29.7

410.8±27.8

−6.3

0.303

Fullness

1

598.3±40.3

591.6±39.9

−1.1

0.832

 

2

584.5±50.7

574.5±49.8

−1.7

0.785

 

3

614.1±47.2

632.3±48.6

3

0.592

 

Average days 1–3

598.8±43.8

599±43.9

0

0.996

Hunger

1

431.5±28.6

418.3±27.7

−3.1

0.651

 

2

434.9±33.6

407.6±31.5

−6.3

0.429

 

3

440.4±32.9

375.4±28

−14.8

0.048

 

Average days 1–3

435.6±28.4

400±26.1

−8.2

0.162

Total appetite

1

469.8±27.3

458.7±26.7

−2.4

0.675

 

2

475.9±31.8

449.4±30.0

−5.6

0.390

 

3

464.5±31.9

414.3±28.4

−10.8

0.106

 

Average days 1–3

470±27.9

440.4±26.2

−6.3

0.215

  1. Abbreviation: PGX, PolyGlycopleX.
  2. Note: P-value is from a linear mixed-model fit on log scale of area under curve and adjusting for potential sequence and period effects in addition to treatment (significance level P<0.05).
  3. Values shown are mean±s.e.; n=35.